Additionally, M13–NL treatment enhanced the composition of the intestinal microbiota, bringing it closer to that of low-inflammation IL10−/− mice, and modestly increased the presence of microbial species in intestinal tumors. The gene discussed is IL10; the disease is intestinal neoplasm.